Loyal, a pet biotech company, aims to extend the lifespan of dogs by preventing—or delaying—age-related disease

Loyal, a pet biotech company, aims to extend the lifespan of dogs by preventing—or delaying—age-related disease.

In February 2025 , LOY-002—a prescription pill from Loyal designed to extend healthy lifespan in senior dogs of nearly every size by targeting metabolic dysfunction.

Nearly 46 percent of U.S. households of households are obsessed with their dogs.

Loyal ’s latest pivotal effectiveness trial will run over the course of four years and aims to enroll up to 1,300 dogs.

Loyal reported “no clinically significant adverse effects” in their pilot study that was submitted to the FDA for preliminary efficacy acknowledgement.

Bioethicist Jessica Pierce says there is no real benefit for the dogs in the conversation of prolonging their natural lifespan.

Clegg: "When I hear her paws on the floor coming to greet me after work, I think, Just a little more time, please, please.

But if Emily isn't having a good time anymore, she can't play God. That isn’t any way to live.”.